BRAIN Biotech, a specialist enzyme and biological solutions provider, announced that the European Patent Office has granted a patent (EP4301852 B1) for its CRISPR-BMC nuclease, a novel genome-editing tool. The patent, effective since March 18, 2026, covers European Unitary Patent countries, Great Britain, and Switzerland, with applications pending in the USA, Japan, and other regions. This milestone strengthens the company's intellectual property portfolio and expands commercial prospects for licensing the technology in various industrial applications.
The CRISPR-BMC nuclease family, derived from metagenomic sources, demonstrates high activity in both prokaryotic and eukaryotic organisms, including bacteria, yeasts, fungi, plants, and mammalian cells. BRAIN Biotech leverages this technology to optimize microbial production strains such as E. coli, Bacillus, Pichia, and Aspergillus for efficient production of enzymes, proteins, and small molecules. The precision of CRISPR-BMC enables targeted double-strand breaks, facilitating specific genomic modifications that enhance strain performance and reduce production costs.
Adriaan Moelker, CEO of BRAIN Biotech, emphasized the significance of the patent: “I am very pleased that we have now secured robust patent protection for the CRISPR-BMC nucleases. Our technology helps make manufacturing processes that utilize microorganisms more cost-effective.” He noted that the nucleases complement the previously patented CRISPR-BEC system, both emerging from the BRAINBioIncubator. The company has already granted licenses to firms in diverse fields and plans to expand licensing activities.
Alexander Pelzer, Head of R&D, highlighted the practical benefits: “CRISPR-BMC allows us to accelerate development of production organisms and strain development for customers thanks to its speed and precision.” He added that BRAIN Biotech’s decades of molecular biology expertise ensure reliable implementation across organisms. The technology is particularly valuable for industries relying on microbial fermentation, such as food, life sciences, and biopharmaceuticals.
With this patent, BRAIN Biotech reinforces its position in the genome-editing market, offering a versatile tool for strain optimization. The company’s business model focuses on licensing, enabling customers to integrate CRISPR-BMC into their workflows. As patent protection expands globally, the technology is poised to drive innovation in sustainable bioproduction. For more details, visit BRAIN Biotech Group.
